Abstract
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma.
Highlights
Low-grade serous ovarian cancer (LGSOC) is a rare (< 5%) subset of epithelial ovarian cancer with unique biologic, clinical, and genetic features.[1]. Compared with those with high-grade SOC (HGSOC), the most common histologic subtype of ovarian cancer, patients with LGSOC are diagnosed at a younger age and have a better prognosis.[2,3]
We describe two patients with LGSOC whose clinical management was informed by targetedpanel next-generation sequencing (NGS) performed in our institution
We present clinically relevant alterations identified by OncoPanel in two patients with recurrent LGSOC: a patient with a BRAF V600E mutation who derived clinical benefit from BRAF inhibitor vemurafenib, and a patient with progressive disease after durable response to hormonal therapy whose recurrent tumor harbored an ESR1 mutation associated with resistance to antiestrogen therapy
Summary
Author affiliations and support information (if applicable) appear at the end of this article. Konstantinopoulos, MD, PhD, Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215; e-mail: panagiotis_ konstantinopoulos@ dfci.harvard.edu
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
